NEO Stock Analysis: NeoGenomics | NASDAQ
Diagnostics & Research | NASDAQ, USA | Market Cap: 2.304m USD | 12M Return: 69.8% | US64049M2098 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.2M
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
NeoGenomics, Inc. (NASDAQ: NEO) is a mid-cap healthcare services company that operates a network of cancer-focused clinical laboratories across the United States and the United Kingdom. Founded in 2001 and headquartered in Fort Myers, Florida, the company provides a broad menu of oncology testing services to hospitals, academic centers, pathologists, oncologists, clinicians, clinical laboratories, and pharmaceutical companies. Its capabilities span cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry with digital imaging, molecular testing, and morphologic analysis. The company also supports pharmaceutical clients oncology drug development programs from discovery through commercialization, making it both a clinical diagnostic provider and a partner in the precision oncology and companion diagnostics space, an area that has grown in importance as targeted cancer therapies become more prevalent.
- Clinical Services volume growth accelerates test revenue
- Pharma Services backlog expands amid oncology trial demand
- Medicare reimbursement cuts pressure oncology test margins
| Net Income: -32.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA -0.84 > 1.0 |
| NWC/Revenue: 37.31% < 20% (prev 40.11%; Δ -2.80% < -1%) |
| CFO/TA 0.00 > 3% & CFO 4.28m > Net Income -32.3m |
| Net Debt (384.3m) to EBITDA (32.3m): 11.91 < 3 |
| Current Ratio: 3.53 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.6m) vs 12m ago 0.52% < -2% |
| Gross Margin: 43.80% > 18% (prev 43.46%; Δ 0.34% > 0.5%) |
| Asset Turnover: 57.26% > 50% (prev 51.58%; Δ 5.67% > 0%) |
| Interest Coverage Ratio: -10.15 > 6 (EBIT TTM -32.9m / Interest Expense TTM 3.25m) |
| A: 0.21 (Total Current Assets 410.1m - Total Current Liabilities 116.2m) / Total Assets 1.38b |
| B: -0.33 (Retained Earnings -456.2m / Total Assets 1.38b) |
| C: -0.02 (EBIT TTM -32.9m / Avg Total Assets 1.38b) |
| D: 1.39 (Book Value of Equity 800.6m / Total Liabilities 576.3m) |
| Altman-Z'' = 1.62 = BB |
| DSRI: 1.23 (Receivables 213.4m/155.8m, Revenue 787.8m/709.2m) |
| GMI: 0.99 (GM 43.46% / 43.80%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.11 (Revenue 787.8m / 709.2m) |
| TATA: -0.03 (NI -32.3m - CFO 4.28m) / TA 1.38b) |
| Beneish M = -2.79 (Cap -4..+1) = A |
As of November 05, 2026, the stock is trading at USD 17.15 with a total of 1,149,921 shares traded. Over the past week, the price has changed by -4.67%, over one month by -10.35%, over three months by +5.28% and over the past year by +69.80%.
Current recommended Stop Loss: 14.70 (which is 14.3% or 2.7 ATR below the current price).
NeoGenomics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NEO.
- StrongBuy: 7
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.3 | 30% |
P/E Forward = 222.2222
P/S = 3.0061
P/B = 2.9416
P/EG = 2.0871
Revenue TTM = 787.8m USD
EBIT TTM = -32.9m USD
EBITDA TTM = 32.3m USD
Long Term Debt = 374.7m USD (from longTermDebt, last quarter)
Short Term Debt = 6.00m USD (from shortTermDebt, last quarter)
Debt = 523.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 74.5m
Net Debt = 384.3m USD (calculated: Debt 523.6m - CCE 139.3m)
Enterprise Value = 2.69b USD (2.30b + Debt 523.6m - CCE 139.3m)
Interest Coverage Ratio = -10.15 (Ebit TTM -32.9m / Interest Expense TTM 3.25m)
EV/FCF = -94.04x (Enterprise Value 2.69b / FCF TTM -28.6m)
FCF Yield = -1.06% (FCF TTM -28.6m / Enterprise Value 2.69b)
FCF Margin = -3.63% (FCF TTM -28.6m / Revenue TTM 787.8m)
Net Margin = -4.10% (Net Income TTM -32.3m / Revenue TTM 787.8m)
Gross Margin = 43.80% ((Revenue TTM 787.8m - Cost of Revenue TTM 442.7m) / Revenue TTM)
Gross Margin QoQ = 46.16% (prev 45.56%)
Tobins Q-Ratio = 1.95 (Enterprise Value 2.69b / Total Assets 1.38b)
Interest Expense / Debt = 0.62% (Interest Expense 3.25m / Debt 523.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -26.0m (EBIT -32.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.53 (Total Current Assets 410.1m / Total Current Liabilities 116.2m)
Debt / Equity = 0.65 (Debt 523.6m / totalStockholderEquity, last quarter 800.6m)
Debt / EBITDA = 11.91 (Net Debt 384.3m / EBITDA 32.3m)
Debt / FCF = -13.45 (negative FCF - burning cash) (Net Debt 384.3m / FCF TTM -28.6m)
Total Stockholder Equity = 812.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.35% (Net Income -32.3m / Total Assets 1.38b)
RoE = -3.97% (Net Income TTM -32.3m / Total Stockholder Equity 812.9m)
RoCE = -2.77% (EBIT -32.9m / Capital Employed (Equity 812.9m + L.T.Debt 374.7m))
RoIC = -2.12% (negative operating profit) (NOPAT -26.0m / Invested Capital 1.23b)
WACC = 5.61% (E(2.30b)/V(2.83b) * Re(6.77%) + D(523.6m)/V(2.83b) * Rd(0.62%) * (1-Tc(0.21)))
Discount Rate = 6.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 87.31 | Cagr: 106.0%
[DCF] Fair Price = unknown (Cash Flow -28.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.22 | # QB: 0
Revenue Correlation: 99.93 | Revenue CAGR: 10.66% | SUE: 0.72 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.06 | Chg30d=-6.78% | Revisions=-30% | Analysts=8
EPS current Year (2026-12-31): EPS=0.20 | Chg30d=+9.47% | Revisions=+50% | GrowthEPS=+66.7% | GrowthRev=+11.0%
EPS next Year (2027-12-31): EPS=0.34 | Chg30d=-0.27% | Revisions=+0% | GrowthEPS=+68.6% | GrowthRev=+9.5%
[Analyst] Revisions Ratio: +0% (up=6, down=6)